

STEP THERAPY POLICY

- POLICY:** Naloxone Injection Step Therapy Policy
- Evzio® Auto-Injector (naloxone hydrochloride 0.4 mg or 2 mg injection – Kaleo, authorized generic to the 2 mg injection [brand and generic discontinued])

REVIEW DATE: 05/25/2022

OVERVIEW

Evzio Auto-Injector (naloxone HCl 0.4 mg or 2 mg injection for SC or IM use, authorized generic to the 2 mg injection) is indicated for the **emergency treatment of known or suspected opioid overdose**, as manifested by respiratory and/or CNS depression in adults and pediatric patients.^{1,2} As of September 2020, Evzio and its authorized generic have been discontinued.

Evzio Auto-Injector provides electronic voice instructions to the user; if the electronic voice instructions do not work for any reason, the Evzio auto-injector will still work.^{1,2} Evzio is intended for immediate administration as emergency therapy in settings where opioids may be present, and it is not a substitute for emergency medical care.

Generic naloxone HCl injection is indicated for the **complete or partial reversal of narcotic depression, including respiratory depression**, induced by opioids including natural and synthetic narcotics, propoxyphene, methadone and certain narcotic-antagonist analgesics (e.g., nalbuphine, pentazocine and butorphanol).^{3,4} Naloxone HCl injection is also indicated for the diagnosis of suspected acute opioid overdose and may be useful as an adjunctive agent to increase blood pressure in the management of septic shock.

Dosing for naloxone HCl injection in an adult with known or suspected overdose is 0.4 mg to 2 mg per dose, up to a total dose of 10 mg.^{3,4} If no response is observed after 10 mg of naloxone HCl, the diagnosis of opioid-induced or partial opioid-induced toxicity should be questioned. Naloxone HCl injection may be administered intravenously (IV), intramuscularly (IM), or subcutaneously (SC); additionally, naloxone injection has been used intranasally using a nasal atomizer. The most rapid onset of action is achieved by IV administration, and this route of administration is recommended in emergency situations when administered by trained healthcare professionals.

All of the naloxone HCl injectable products are indicated for use in adults and pediatric patients.¹⁻⁴ Table 1 provides information on the available injectable naloxone strengths and dosage forms.

Table 1. Available Dosage Forms and Strengths of Naloxone Injectable Products.

Product	Strength(s)	Dosage Form	Additional Supplies Needed to Administer
Evzio®, authorized generic	0.4 mg/0.4 mL 2 mg/0.4 mL	Prefilled auto-injector with electronic voice instructions	None
Naloxone HCl	2 mg/2 mL	<ul style="list-style-type: none">• 2 mL prefilled syringe with needle• 2 mL prefilled syringe without needle	<ul style="list-style-type: none">• None if using IM/IV• Needle or MAD
Naloxone HCl	0.4 mg/mL	<ul style="list-style-type: none">• Vial (1 mL and 10 mL)• 1 mL carpuject cartridge	<ul style="list-style-type: none">• Syringe and needle or MAD• Carpuject syringe system

HCl – Hydrochloride; IM – Intramuscular; IV – Intravenous; MAD – Mucosal atomization device.

POLICY STATEMENT

05/25/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

This program has been developed to encourage the use of a Step 1 Product prior to the use of a Step 2 Product. If the Step Therapy rule is not met for a Step 2 Product at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 1 year in duration.

Automation: None.

Step 1: naloxone 0.4 mg/mL vial, naloxone 0.4 mg/mL syringe, naloxone 2 mg/2 mL syringe

Step 2: Evzio, naloxone 2 mg/0.4 ml auto-injector (authorized generic to Evzio)

CRITERIA

1. If the prescriber can confirm that the patient's caregiver is blind or significantly visually impaired, approve Evzio or its authorized generic.

Note: If the prescriber does not know or cannot confirm that the patient's caregiver is blind or significantly visually impaired, the request should NOT be approved.

Note: Denial reason is: Coverage is provided in situations where the prescriber can confirm that the patient's caregiver is blind or significantly visually impaired. The patient should be prescribed naloxone injection, Narcan Nasal Spray, or Kloxxado.

2. No other exceptions are recommended.

REFERENCES

1. Evzio® 0.4 mg/0.4 mL auto-injector [prescribing information]. Richmond, VA: kaleo; April 2014.
2. Evzio® 2 mg/0.4 mL auto-injector [prescribing information]. Richmond, VA: kaleo; October 2016.
3. Naloxone 0.4 mg/mL injection [prescribing information]. Rockford, IL: Mylan; April 2021.
4. Naloxone 1 mg/mL injection [prescribing information]. So. El Monte, CA: International Medication Systems; March 2016.